Collegium to Present ADHD Research at Upcoming Congresses
The pharmaceutical company will share seven new research abstracts focused on pediatric and adult ADHD treatment.
Updated on Oct. 21, 2026 in Autism
Live Poll
Do you feel current ADHD management options address the daily practical challenges families face?
Beginning October 26, 2026, Collegium Pharmaceutical will present seven research abstracts covering ADHD treatment at upcoming medical conferences. These presentations will highlight findings from Phase 4 studies, retrospective clinical analyses, and caregiver surveys.
Why it matters
The research aims to provide a deeper understanding of the daily needs and experiences of those managing ADHD across various age groups and clinical settings. This data is intended to support more effective treatment approaches for millions of affected individuals.
Collegium Pharmaceutical is set to present seven research abstracts detailing pediatric AZSTARYS studies and retrospective JORNAY PM analyses. These findings address the healthcare needs of 22.5 million Americans currently diagnosed with ADHD.
The players
Collegium Pharmaceutical
A pharmaceutical company that focuses on developing and commercializing treatments for various medical conditions, including ADHD.
The details
The presentations will utilize retrospective real-world analyses and survey data to evaluate medication efficacy and caregiver perspectives. These efforts focus on improving the clinical management of ADHD in both pediatric and adult populations.
Timeline
October 26-31, 2026: AACAP 2026 Annual Meeting
November 5-8, 2026: NEI Fall Congress
Health Landscape
The upcoming research presentations at the American Academy of Child and Adolescent Psychiatry 2026 Annual Meeting represent a significant step in the ongoing development of evidence-based ADHD therapeutic protocols. Such academic forums act as the primary engines for disseminating real-world efficacy data to clinicians.
This research provides clinical insights that may eventually influence how healthcare providers prescribe and manage ADHD medications for children and adults. Patients and caregivers should discuss these evolving treatment strategies with their doctors.
The takeaway
Ongoing clinical studies are essential for refining medication regimens for millions of ADHD patients in the United States. Families should continue to prioritize consulting with medical professionals as new, real-world data becomes available.
Further reading
Learn more about the latest research in the field on the United States Autism page.
Live Poll
Do you feel current ADHD management options address the daily practical challenges families face?
